Proactive Investors - Run By Investors For Investors

Acasti Pharma Inc receives new patents in Israel, Mexico and Chile as it advances its cardiovascular drug

The company's flagship drug CaPre is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis
vials of blood
CaPre is primarily composed of certain omega-3 fatty acids that are thought to contribute to promote healthy heart, brain and visual function

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) has been granted patents related to the development of its prescription drug candidate CaPre in Israel, Mexico and Chile, the pharmaceutical company announced Wednesday.

CaPre is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis.

Derived from krill oil, CaPre is primarily composed of certain omega-3 fatty acids that are thought to contribute to promote healthy heart, brain and visual function by reducing inflammation and types of fat known as triglycerides. Hypertriglyceridemia is an elevated level of that fat, or lipids, found in the blood.

READ: Ventripoint Diagnostics to bring its cardiac-imaging technology to France

The new patents, which are valid until 2030, relate to a concentrated phospholipid composition and method of using the same for modulating blood lipids, the company said in a statement.

“We are pleased to announce the granting of these latest patents, which further strengthen and expand the Acasti’s intellectual property portfolio,” said Pierre Lemieux, COO and CSO of Acasti.

According to Acasti, Israel, Mexico and Chile each represent important markets for potential commercialization of CaPre.

“The granting of these patents is another important milestone for Acasti and is in line with our commitment to build a global portfolio of patents to ensure long-lasting and comprehensive protection of our products,” Lemieux said in a statement.

Phase 3 testing underway

Phase 3 testing of CaPre is currently underway and will evaluate the safety and efficacy of the drug for the treatment of patients with severe hypertriglyceridemia. The study is a double-blind, placebo-controlled, 26-week, two-trial Phase 3 clinical program. Phase 1 and 2 are running in conjunction and will randomize a total of approximately 500 patients.

The program is being conducted at approximately 150 sites across the U.S., Canada and Mexico. Acasti anticipates reporting topline results by the end of 2019.

Shares of Acasti were trading at C$1.08 in Toronto and at US$0.81 in the US on Wednesday morning.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full ACST profile View Profile

Acasti Pharma Inc. Timeline

Related Articles

A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use